secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001213900-25-062194
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs
--------------------------------------------------------------------------------

- Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
- Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.
- CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.
- Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.
- Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/0001213900-25-062194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/ea0248394-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer